Kisspeptin-54 is the full-length active form of the KISS1 gene product, representing the most important discovery in reproductive neuroendocrinology in decades. It sits at the top of the reproductive hormone cascade, making it a unique therapeutic target for fertility disorders that avoids the receptor desensitization problems of GnRH analogs.
Dosage Information (Research Use)
Research/IVF: 6.4-12.8 nmol/kg SC or IV bolus. For oocyte maturation: single SC dose 36 hours before retrieval. Clinical research compound — not commercially available as a therapeutic.
Reconstitution & Handling
Reconstitute in sterile saline.
Half-Life & Pharmacokinetics
~4 minutes (IV); ~27 minutes (SC)
Reported Observations in Literature
Generally well tolerated in clinical studies. Mild injection site reactions. Transient flushing. No OHSS reported when used as IVF trigger (major safety advantage over hCG).
Key Research References
- Dhillo WS et al. “Kisspeptin-54 stimulates the hypothalamic-pituitary gonadal axis in human males.” J Clin Endocrinol Metab. 2005;90:6609-15
- Abbara A et al. “Kisspeptin as a trigger for oocyte maturation in IVF.” N Engl J Med. 2017;376:1975-6